Adc Therapeutics Sa Stock Alpha and Beta Analysis
| ADCT Stock | USD 1.72 0.07 4.24% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ADC Therapeutics SA. It also helps investors analyze the systematic and unsystematic risks associated with investing in ADC Therapeutics over a specified time horizon. Remember, high ADC Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ADC Therapeutics' market risk premium analysis include:
Beta (0.33) | Alpha (0.28) | Risk 10.95 | Sharpe Ratio (0.04) | Expected Return (0.42) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ADC |
ADC Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ADC Therapeutics market risk premium is the additional return an investor will receive from holding ADC Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ADC Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ADC Therapeutics' performance over market.| α | -0.28 | β | -0.33 |
ADC Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ADC Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how ADC Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ADC Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how ADC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ADC Therapeutics shares will generate the highest return on investment. By understating and applying ADC Therapeutics stock market price indicators, traders can identify ADC Therapeutics position entry and exit signals to maximize returns.
ADC Therapeutics Return and Market Media
The median price of ADC Therapeutics for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 is 2.03 with a coefficient of variation of 22.34. The daily time series for the period is distributed with a sample standard deviation of 0.51, arithmetic mean of 2.26, and mean deviation of 0.43. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | What To Expect From ADC Therapeutics SA Q3 2024 Earnings | 11/06/2024 |
2 | ADC Therapeutics SA Reports Q3 Loss, Lags Revenue Estimates - MSN | 11/20/2024 |
3 | Sphera Funds Management LTD. Lowers Stock Holdings in ADC Therapeutics SA | 12/05/2024 |
4 | Disposition of 26656 shares by Redmile Group, Llc of ADC Therapeutics subject to Rule 16b-3 | 12/06/2024 |
5 | ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Tre... | 12/09/2024 |
6 | Acquisition by Redmile Group, Llc of 50000 shares of ADC Therapeutics at 2.28 subject to Rule 16b-3 | 12/10/2024 |
7 | Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors | 12/12/2024 |
8 | Acquisition by Redmile Group, Llc of 50000 shares of ADC Therapeutics at 2.1148 subject to Rule 16b-3 | 12/17/2024 |
9 | Disposition of 44996 shares by Redmile Group, Llc of ADC Therapeutics at 1.633 subject to Rule 16b-3 | 12/18/2024 |
10 | ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L Diffuse Large B-Cell ... | 12/30/2024 |
11 | Is ADC Therapeutics SA Worth US2.0 Based On Its Intrinsic Value | 01/02/2025 |
12 | Institutional owners may consider drastic measures as ADC Therapeutics SAs recent US21m drop adds to long-term losses | 01/14/2025 |
13 | Disposition of 31000 shares by Azelby Robert of ADC Therapeutics at 2.29 subject to Rule 16b-3 | 01/23/2025 |
14 | ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference -January 30, 2025 at 0716 am EST - Marketscreener.com | 01/30/2025 |
About ADC Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ADC or other stocks. Alpha measures the amount that position in ADC Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.16 | 0.19 | 0.18 | Days Of Inventory On Hand | 2.3K | 2.1K | 2.2K |
ADC Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of ADC Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADC Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ADC Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ADC Therapeutics. Please utilize our Beneish M Score to check the likelihood of ADC Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ADC Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.